6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05205291 (ClinicalTrials.gov) | February 1, 2022 | 9/11/2021 | Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR | Molecular Imaging of LPS-induced Microglial Activation in Parkinson's Disease (PD). A TSPO PET-MR Imaging Study | Neurodegenerative Diseases;Parkinson Disease | Drug: Lipopolysaccharide;Radiation: PET/MR with [11C]PBR28 | University of Exeter | NULL | Recruiting | 50 Years | 85 Years | All | 24 | United Kingdom |